Building a biosimilar product portfolio for the long term

Formycon covers the entire range of biosimilar medicines development, from technical-pharmaceutical development to clinical trials, all the way through to preparation and submission of dossiers for regulatory approval by international authorities.

RANIBIZUMABReference product: Lucentis®¹


USTEKINUMABReference product: Stelara®²


AFLIBERCEPTReference product: Eylea®³



The company currently has several biosimilar product candidates in advanced development – FYB201, FYB202, FYB203 and FYB206 – with each of these positioned to potentially compete against existing blockbuster biopharmaceuticals, each with sales in the billions of dollars. The market potential for our product candidates is thus substantial.

Of these four biosimilar projects, major out-licensing deals have already been signed for two. Our out-licensing partner for FYB201 is Bioeq AG (formerly Bioeq IP AG), a joint venture of Santo Holding AG and Polpharma Group, while FYB203 is partnered with Klinge Biopharma GmbH (part of Santo Holding (Deutschland) GmbH). A third project, FYB202, has been transferred into a joint venture arrangement with Aristo Pharma GmbH, part of the Strüngmann Group.

Formycon regularly publishes updated information regarding the advances in its biosimilar development pipeline, which is expected to be further expanded in the coming years.

¹ Lucentis® is a registered trademark of Genentech, Inc.
² Stelara® is a registered trademark of Johnson & Johnson
³ Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc.